Seeking Alpha

LSYMD's  Instablog

LSYMD
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • Hepatitis C: JNJ Approved, GILD Next 0 comments
    Nov 24, 2013 2:10 PM | about stocks: JNJ, GILD

    On Friday, the FDA approved JNJ's simeprevir (Olysio) for treatment of Genotype 1 Hepatitis C patients, in combination with ribavirin and interferon. Pre-screening for a genetic polymorphism more common in Genotype 1a will exclude some patients. I believe that the near term greatest potential for Olysio will be in off-label combination with GILD's soon to be approved sofosbuvir, based on the COSMOS study. Also, we shall have definitive pricing information for both drugs in the upcoming weeks. I expect analysts to increase projections for this market, which I forecast to become the largest pharmaceutical category in history.

    Disclosure: I am long JNJ, GILD.

    Stocks: JNJ, GILD
Back To LSYMD's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.